REGENXBIO INC. DL-,0001 WKN: A140E0 ISIN: US75901B1070 Kürzel: RB0 Forum: Aktien Thema: Hauptdiskussion

https://www.prnewswire.com/news-releases/regenxbio-reports-third-quarter-2022-financial-results-and-recent-operational-highlights-301667151.html

REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD https://www.prnewswire.com/news-releases/regenxbio-announces-additional-positive-interim-data-from-trials-of-rgx-314-for-the-treatment-of-wet-amd-301638557.html

https://www.prnewswire.com/news-releases/regenxbio-presents-additional-positive-interim-data-from-the-phase-iiiiii-campsiite-trial-of-rgx-121-for-the-treatment-of-mps-ii-hunter-syndrome-at-the-society-for-the-study-of-inborn-errors-of-metabolism-ssiem-annual-sympo-301615279.html

REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2022-financial-results-and-recent-operational-highlights-301599291.html

REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II https://www.prnewswire.com/news-releases/regenxbio-announces-intention-to-file-a-biologics-license-application-using-the-accelerated-approval-pathway-for-rgx-121-an-aav-therapeutic-for-the-treatment-of-mps-ii-301598783.html • FDA will consider an accelerated approval pathway for RGX-121; BLA filing expected in 2024 • Pivotal program is active and enrolling patients • RGX-121 is a potential first-in-class, one-time gene therapy for the treatment of MPS II • Internal cGMP manufacturing process expected to support BLA ...

https://www.prnewswire.com/news-releases/regenxbio-opens-state-of-the-art-gene-therapy-manufacturing-facility-301565323.html

REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights https://www.prnewswire.com/news-releases/regenxbio-reports-first-quarter-2022-financial-results-and-recent-operational-highlights-301540075.html

REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights https://www.prnewswire.com/news-releases/regenxbio-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-operational-highlights-301493248.html

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022 https://www.prnewswire.com/news-releases/regenxbio-presents-positive-initial-data-from-phase-iii-trial-of-rgx-111-for-the-treatment-of-severe-mps-i-at-18th-annual-worldsymposium-2022-301478817.html

REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy https://www.prnewswire.com/news-releases/regenxbio-announces-orphan-drug-designation-granted-to-rgx-202-a-novel-gene-therapy-candidate-for-the-treatment-of-duchenne-muscular-dystrophy-301429654.html

REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021 https://www.prnewswire.com/news-releases/regenxbio-presents-additional-positive-interim-data-from-trials-of-rgx-314-in-wet-amd-and-diabetic-retinopathy-using-suprachoroidal-delivery-at-aao-2021-301423126.html

RegenxBio’s deal with AbbVie just closed. It could mean more than $1B for the local company. https://www.bizjournals.com/washington/news/2021/11/12/regenxbio-abbvie-close-deal-eye-disease-treatment.html RegenxBio Inc. has closed a massive development and commercialization deal with Chicago’s AbbVie Inc., two months after announcing the agreement that stands to shovel move than $1 billion to the Rockville biotech. The partners said Tuesday they have closed that transaction, to bring to market the local gene therapy company’s treatment candidate for multiple eye diseases, now in clinical trials for wet age-related macular degeneration (AMD), diabetic retinopathy and other chronic retinal illnesses. Now, AbbVie (NYSE: ABBV) pays RegenxBio (NASDAQ: RGNX) $370 million upfront. But the deal also carries the potential for an additional $1.38 billion in development, regulatory and commercial milestones. ...

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=847521

REGENXBIO Reports Third Quarter 2021 Financial Results and Operational https://www.prnewswire.com/news-releases/regenxbio-reports-third-quarter-2021-financial-results-and-operational-highlights-301414492.html

Regenxbio-Solid Biosciences' PDC releases white paper for AAV gene therapy development https://seekingalpha.com/news/3762777-regenxbio-solid-biosciences-pdc-releases-white-paper-for-aav-gene-therapy-development ... The draft white paper proposes a framework that can be applied to AAV gene therapies to facilitate the use of the accelerated approval pathway at the U.S. FDA. ...

REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting https://finance.yahoo.com/news/regenxbio-presents-positive-initial-data-152300587.html